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Abstract
Objective: Transient ischemic attacks (TIA) and minor strokes are important
risk factors for recurrent strokes. Current stroke risk prediction scores such as
ABCD2, although widely used, lack optimal sensitivity and specificity. Elevated
urinary albumin excretion predicts cardiovascular disease, stroke, and mortality.
We explored the role of microalbuminuria (using albumin creatinine ratio
(ACR)) in predicting recurrence risk in patients with TIA and minor stroke.
Methods: Urinary ACR was measured on a spot sample in 150 patients attend-
ing a daily stroke clinic with TIA or minor stroke. Patients were followed up at
day 7, 30, and 90 to determine recurrent stroke, cardiovascular events, or death.
Eligible patients had a carotid ultrasound Doppler investigation. High-risk
patients were defined as those who had an event within 90 days or had >50%
internal carotid artery (ICA) stenosis. Results: Fourteen (9.8%) recurrent events
were reported by day 90 including two deaths. Fifteen patients had severe ICA
stenosis. In total, 26 patients were identified as high risk. These patients had a
higher frequency of previous stroke or hypercholesterolemia compared to low-
risk patients (P = 0.04). ACR was higher in high-risk patients (3.4 [95% CI
2.2–5.2] vs. 1.7 [1.5–2.1] mg/mmol, P = 0.004), independent of age, sex, blood
pressure, diabetes, and previous stroke. An ACR greater than 1.5 mg/mmol pre-
dicted high-risk patients (Cox proportional hazard ratio 3.5 (95% CI 1.3–9.5,
P = 0.01). Interpretation: After TIA or minor stroke, a higher ACR predicted
recurrent events and significant ICA stenosis. Incorporation of urinary ACR
from a spot sample in the acute setting could improve risk stratification in
patients with TIA and minor stroke.
Introduction
Stroke is the third most common cause of death and a
leading cause of disability worldwide.1 Despite, or possi-
bly because of, recent trends in reducing stroke mortality,
the healthcare and social support consequences are
increasing.2 Transient ischemic attack (TIA) and minor
stroke are the most important risk factors for recurrent
stroke and also predict long-term mortality.3,4 Nearly, a
quarter of patients presenting with stroke have a history
of TIA in the 3 months prior to the index event, with
half of these recurring within the first week.5 However,
this high-risk group represents only 10% of patients who
present to TIA clinics.6,7 Therefore, accurate detection
and risk stratification is critical to identify those patients
who are at highest risk of stroke in order to appropriately
allocate intensive risk-reducing interventions such as
urgent carotid endarterectomy, while reassuring those at
lower risk.
The majority of patients with TIA/minor stroke present
to a primary care physician or the emergency department
after resolution of their symptoms. There are several risk
stratification tools utilized in these settings such as
ABCD2 (awarding points for Age, presenting Blood pres-
sure, Clinical features of unilateral weakness or aphasia,
Duration of symptoms and Diabetes),8 California score6
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and imaging based scoring systems.9,10 However, these
tools still lack optimal sensitivity and specificity.11 Fur-
ther, scores involving imaging are expensive, time con-
suming, and not available at all centers. Recent studies
seeking to identify biomarkers that could predict risk
have shown modest association between these markers
and high-risk patients, with only interleukin-6 and CRP
significantly predicting recurrent stroke.12 These tests are
not routinely or rapidly available for primary care and
emergency physicians to risk stratify patients presenting
with TIA/minor stroke. The urgent surgical correction of
severe internal carotid artery (ICA) stenosis is one of the
most effective strategies to reduce the risk of evolution to
completed stroke.10 However, an apparently “low-risk”
ABCD2 score <4 could miss up to 40% of patients with
severe ICA stenosis.13 Indeed, some studies suggest
patients with an ABCD2 score <4 (considered to be “low
risk”) have similar 90 day stroke risk as patients with
ABCD2 score ≥4 (deemed “high risk”).14 This brings the
need for refinement of risk tools or simple bedside tests
that allow primary care and emergency physicians to
identify high-risk patients needing hospital admission for
urgent assessment and imaging.
Increased urinary albumin excretion rate has been
shown to predict incident stroke and heart failure in
those with diabetes and cardiovascular disease, and
mortality post stroke in those without diabetes indepen-
dent of conventional cardiovascular risk factors such as
hypertension, diabetes, and smoking.15–18 Urinary albu-
min creatinine ratio (ACR) is a well recognized proxy for
urinary albumin excretion rate. It can be assessed using
simple and relatively inexpensive point of care equipment.
We aimed to determine the feasibility of using urinary
ACR to improve risk stratification in patients presenting
with TIA or minor stroke.
Methods
Consecutive patients with suspected TIA/minor stroke
presenting to the daily stroke clinic in a single large dis-
trict teaching hospital over a 9-month period were
approached and written informed consent was sought.
After consent, basic demographics, including age, sex,
height, weight, past medical history, and ABCD2 score
were recorded. Time from onset of symptoms to assess-
ment and enrollment in the study was documented. A
specimen of urine was collected from participants during
their visit and ACR was measured using a point of care
analyzer (The AfinionTM AS100 Analyzer, Axis Shield,
Dundee, UK). This system uses an immunometric mem-
brane flow-through principle for albumin measurement
and an enzymatic colorimetric test for creatinine quantifi-
cation 19 and reports, in approximately 5 min, an ACR in
the range 0.1–140 mg/mmol with a coefficient of variance
of 4.6–6%.19 Eligible patients (anterior circulation events
and patients fit for surgery) had carotid ultrasound
Doppler studies. All carotid ultrasound studies were
performed by SVT (Society of Vascular Technologists)
accredited clinical scientists using Toshiba Aplio MX.
The NASCET criteria were used to identify severe ICA
stenosis.20.
Participants were followed up by telephone on day 7,
30, and 90 for the primary end points of any further car-
diovascular event, stroke, and death. Outcome events
were verified by an independent clinician, blinded to the
ACR, by examination of clinical records if they attended
the hospital or by verifying their clinical symptoms from
the research records if patients did not seek further
medical advice. High-risk patients were defined as those
patients who had recurrent vascular events (either
cerebro- or cardiovascular) or death within 90 days or
had severe ICA stenosis (>50% NASCET). The study pro-
tocol was approved by the Southwest Research Ethics
Committee (REC Reference 10/H0203/57).
Statistical analysis
Data were treated as continuous variables where
appropriate. All normally distributed data are presented
as mean  SD. Skewed data were appropriately log
transformed and presented as geometric means (95% CI).
Statistical significance for categorical variables was esti-
mated using the chi-squared test, and Student’s t-test was
used for continuous variables. Independence of urinary
ACR (as a risk predictor) from diabetes and other mea-
sures of the ABCD2 score was assessed using logistic
regression. Statistical significance was considered at
P < 0.05. Statistical analysis was performed using Stata SE
12.1 (Mac version: Statacorp Ltd, Texas). This study was
powered to detect a difference of 0.5SD in ACR between
high-risk and low-risk patients allowing for 15% drop out
with 80% power at a significance of 0.05 by recruiting
150 participants. Prespecified exploratory analyses were
dependent on the primary outcome of a difference in
ACR between high- and low-risk patients being fulfilled.
These included analyses of patients experiencing recurrent
events (i.e., excluding those deemed high risk because of
ICA stenosis), patients in the “acute phase” (within
7 days of index event), and assessing the independence of
findings from the conventional risk score ABCD2.
Results
Five hundred and twenty-three patients attending the
daily stroke/TIA clinic in a large district general hospital
were screened over 9 months period. Two hundred and
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sixty-six patients met the screening criteria for the study,
out of these, 150 patients consented to take part in the
study. The main reasons why eligible patients did not take
part in the study were patient could not produce a urine
sample, evidence of UTI on urine test, unable to provide
informed consent, personal reasons, and involvement in
other clinical trials. Follow-up was completed in all par-
ticipants to day 90, with no patients lost to follow-up.
Seven patients were subsequently excluded after the diag-
nosis was revised as a stroke mimic. There was an
approximately equal distribution of males (56%) and
females, and baseline characteristics were representative of
the usual clinic population (Table 1). All patients with
confirmed diagnosis of TIA/minor stroke were com-
menced on secondary prevention with antiplatelet or anti-
coagulants as well as statin therapy unless contraindicated
in accordance with the current national guidelines.21.
Over the 90 days of the study, 14 out of the 143
patients included in the analysis (9.8%) had further
events (12 recurrent strokes/TIA, two cardiac events, and
two deaths [two patients had more than one event]). One
hundred and thirteen of patients included in analysis had
anterior circulation events that warranted urgent carotid
ultrasound Doppler assessments of whom 15 had severe
ICA stenosis (13%) amenable to urgent surgical interven-
tion. Three of those with recurrent events also had severe
ICA stenosis resulting in a total of 26 high-risk patients
identified. High-risk patients had a higher incidence of
previous stroke and hypercholesterolemia (P = 0.04) than
lower risk patients, but were otherwise similar (Table 1).
Notably, ABCD2 score was statistically not different and
numerically lower in the high-risk population. ACR was
higher in the high-risk patients compared to the lower
risk group 3.4 (95% CI: 2.2–5.2) versus 1.7 (1.5–2.1) mg/
mmol, respectively; P = 0.004). This remained significant
after adjustment for age and sex (adjusted ACR 3.1
[2.1–4.6] vs. 1.8 [1.5–2.2], P = 0.008) (Table 2).
Further adjustment to blood pressure, diabetes, previ-
ous stroke, and history of hypercholesterolemia, did
not alter the results (adjusted ACR 3.4 [2.4–5.0] vs. 1.7
[1.4–2.0] mg/mmol; P < 0.0001) (Table 2).
Nine patients had a recurrent event within 7 days of
the index event. The only distinguishing feature of these
individuals was a higher ACR at presentation (ACR 4.0
[2.0–7.9] vs. 1.9 [1.6–2.3] mg/mmol, respectively, P =
0.04).
An ABCD2 score of ≥4 (traditionally regarded as high
risk) did not predict subsequent events or the need for
carotid endarterectomy. An ABCD2 score of ≥4 was
not associated with elevated ACR (2.1 [1.7–2.6] vs. 1.8
[1.4–2.5] mg/mmol for those with ABCD2 < 4; P = 0.4).
Adjustment for ABCD2 score either as a continuous or
categorical variable did not affect the predictive role of
ACR (adjusted ACR 3.2 [2.1–4.7] vs. 1.8 [1.5–2.2] mg/
mmol, P = 0.017; Table 2).
Table 1. Sample characteristics stratified by High-risk and Low-risk
patients (High-risk patients defined as recurrent events within 90 days
or ICA stenosis >50% (NASCET)).
High-risk
patients
Low-risk
patients
Sig
(2-tailed)
Number 26 117
Age (years) 74  10 74  11 0.2
Sex
Females(%) 12 (46) 51 (44) 0.8
Males(%) 14 (54) 66 (56)
Height (m) 1.64  0.09 1.68  0.10 0.08
Weight (Kg) 72  19 76  15 0.27
BMI (kg/m2) 27  5 27  4 0.7
SBP (mmHg) 140  19 141  32 0.8
DBP (mmHg) 74  11 77  16 0.5
MAP (mmHg) 96  12 101  12 0.08
ABCD2 4.3  1.4 4  1.5 0.25
DM (%) 4 (15) 11 (9) 0.37
IHD (%) 6 (23) 20 (17) 0.47
High cholesterol (%) 10 (38) 23 (20) 0.04
Previous stroke (%) 10 (38) 23 (20) 0.04
Retinopathy (%) 0 (0) 3 (3) 0.4
eGFR (ml/min/1.73 m2) 60  38 68  27 0.16
Figures presented as mean  SD (except where indicated).
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean
arterial pressure; ABCD2 (A = age, B = BP, C = clinical features, D =
duration of symptoms + Diabetes); DM, diabetes mellitus; IHD,
ischemic heart disease; PVD, peripheral vascular disease; eGFR, esti-
mated Glomerular Filtration Rate.
Table 2. Unadjusted and adjusted albumin creatinine ratio (ACR)
(geometric mean (95% CI) mg/mmol) for High-risk and Low-risk
patients. (High-risk patients defined as recurrent events within 90 days
or ICA stenosis >50% (NASCET)).
Low-risk
patients
High-risk
patients P-value
Unadjusted ACR 1.7 (1.5–2.1) 3.4 (2.2–5.2) 0.004
ACR adjusted for age
and sex
1.8 (1.5–2.2) 3.1 (2.1–4.6) 0.008
ACR adjusted for age,
sex, BP & DM
1.7 (1.4–2.0) 3.4 (2.4–4.9) <0.0001
ACR adjusted for age,
sex, BP, DM, previous
stroke &
hypercholesterolemia
1.7 (1.4–2.0) 3.4 (2.4–5.0) <0.0001
ACR adjusted for ABCD2 1.8 (1.5–2.2) 3.2 (2.1–4.7) 0.017
ACR, albumin creatinine ratio; BP, mean arterial blood pressure, calcu-
lated from the mean of three readings; DM, confirmed diagnosis of
diabetes prior to inclusion in the study; ABCD2, clinically utilized risk
stratification risk into low, medium and high risk of a further event
within 90 days.
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An ACR ≥1.5 had a positive predictive value of 25%
(95% CI: 16%–36%) and a negative predictive value of
90% (95% CI: 80–96%) for high-risk patients.
After adjustment for age, sex, ABCD2 score, SBP, DBP,
previous stroke, history of cardiovascular disease, eGFR,
and hypercholesterolemia, an ACR greater than 1.5 mg/
mmol predicted high-risk patients (Cox proportional haz-
ards: 3.5; 95% CI: 1.3–9.5; P = 0.01), significant ICA steno-
sis (Cox proportional hazard: 4.2; 95% CI: 1.14–15.7;
P = 0.03), and showed a trend for the prediction of
recurrent events (Cox proportional hazards: 4.1; 95% CI:
.91–18.2; P = 0.067). Contrary to ACR, an ABCD2 score ≥
4 did not predict high-risk patients (Cox proportional haz-
ard ratio: 1.9; 95% CI: 0.7–5.4; P = 0.22), severe ICA steno-
sis (1.2; 95% CI: 0.35–4.2; P = 0.75) or recurrent events
(5.4; 95% CI: 0.6–45.5; P = 0.12).
Discussion
We have demonstrated for the first time the potential
utility of a near-patient test for ACR in predicting
patients who will go on to have recurrent episodes or
benefit from urgent carotid scan assessment and surgical
intervention after a minor stroke or TIA. Further, this
was independent of a widely accepted risk stratification
tool, ABCD2 (which incorporates blood pressure and dia-
betes, both thought to be determinants of microalbumin-
uria). ACR is easy to test, can provide an immediate
result and is already widely accepted in primary care as a
prognostic tool in diabetes. Therefore, if confirmed, the
use of ACR could easily be extended to assist with risk
stratification and services allocation in people after TIA
or minor stroke.
Recently, Kiyohara et al. suggested the ABCD3 (an
extra D for “dual” TIA event) or ABCD3-I (I for severe
ICA stenosis) are superior to ABCD2 score in predicting
stroke in patients with TIA.10 However, whereas predic-
tive power may be improved, both proposed scores
involve further delay. Immediate carotid imaging is often
not available to front-line clinicians (family and
emergency physicians) to allow them to risk stratify
patients with suspected TIA. Simple point of care testing
with urinary ACR may improve risk stratification in this
circumstance.
Elevated urinary albumin excretion rate is a recognized
marker of generalized endothelial and microvascular
dysfunction. In the general population, microalbuminuria
predicts cardiovascular events including stroke and all-
cause mortality.15,18 It identifies those patients with
diabetes who are likely to develop atherosclerotic disease
and progression to renal impairment22 and it has strong
association with atherosclerosis.23 In those with recent
myocardial infarction, the urinary albumin excretion is
higher, and stratifying by ACR adds valuable prognostic
information.24 Therefore, the predictive value of microal-
buminuria in the setting of TIA and severe ICA stenosis
is not unexpected.
The mechanism behind the association between
microalbuminuria and incident cardiovascular events is
thought to reflect its role as a marker of increased vascu-
lar permeability and altered homeostasis, coagulation and
endothelial function.25,26 The increased filtration of albu-
min by the renal glomerulus is thought to be due to
changes in the chemical and physical properties of the
endothelial barrier and its glycocalyx.22,27 After acute
vascular events such as myocardial infarction, TIA, or
minor stroke, increased urinary albumin excretion is asso-
ciated with endothelial dysfunction,26 indices of plaque
instability in diabetes and acute coronary syndrome28,
and with subclinical atherosclerosis in patients with
diabetes or hypertension.29 Improving systemic inflamma-
tion, such as through the pleiotropic effect of statins, has
been associated with simultaneous improvements in uri-
nary albumin excretion and CV event rates in patients
with elevated high-sensitivity C-reactive protein
(hsCRP).30 In hypertensive patients treated with standard
therapy, changes in urinary albumin excretion over time
predicted cardiovascular events and patients who
remained normo-albuminuric or showed regression in
their microalbuminuria had a lower incidence of
cardiovascular disease.31 Further studies are needed to
determine whether microalbuminuria represents an easily
accessible therapeutic target amenable to treatment, and if
reductions in microalbuminuria are associated with
reductions in the vascular events they predict.
Study limitations
Our study had limited power to test the independence of
confounders such as diabetes and blood pressure. Never-
theless, the difference in ACR between those with future
events over 90 days or with ICA stenosis requiring
treatment, did remain after adjustment for ABCD2
(which includes a score for the presence of hypertension
or diabetes), or diabetes and hypertension in logistic
regression models, and the small numerical difference
made by adjustment makes residual confounding unlikely.
Further, our study had relatively small numbers, therefore
a larger study sample may be needed to verify the
predictive power of ACR and to identify the most rele-
vant cutoff limit for ACR.
ACR was measured on a single urine sample obtained
during the clinic assessment. There is significant, diurnal
variability in urinary albumin excretion within individu-
als, which might limit the generalizability to
other populations and studies using overnight or 24-hour
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urine collection. However, the pragmatic design
makes this study more applicable to general clinic popula-
tions.
This study did not attempt to subclassify the events by
etiology, such as through the use of TOAST criteria. It is
possible that microalbuminuria has different predictive
roles in the different subtypes of stroke, and it may be
that microalbuminuria is a proxy for the different sub-
types which have a poorer prognosis. However, this study
is seeking to identify a more practical prognostic tool
which can be used at the first assessment of the patient,
when the information necessary for accurate TOAST
classification will not be routinely available.
Conclusion
We have demonstrated for the first time the potential
utility of ACR in patients presenting with TIA and minor
stroke as a prediction tool to assist triaging patients into
high- and low-risk categories. This performed better than
the currently utilized ABCD2 score, and was independent
of clinically apparent confounders such as blood pressure,
diabetes, and previous stroke. Larger-scale studies are
now required to determine whether the use of ACR
would provide a clinically significant risk stratification
tool for front-line physicians, allowing for better alloca-
tion of resources while providing appropriate reassurance
for those at lower risk.
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